Assistant Professor of Medicine, Brown University
Infectious Disease
Dr. Steven P. LaRosa, MD
|
|
Give Review
Doctor Steven P. LaRosa, MD works in the field of Infectious Disease. He researched medicine at Boston University School of Medicine. Boston University School of Medicine is ranked 30/52 in Research/PrimaryCare. He has 1 awards "Regional Top Doctor". Steven LaRosa is a published doctor and has 34 publications published. The lastest was: 'Evaluating the Efficacy and Safety of Two Doses of the Polyclonal Anti-Tumor Necrosis Factor- Fragment Antibody AZD9773 in Adult Patients With Severe Sepsis and/or Se...' Steven LaRosa accepts all Medicare patients.
Publications
- Evaluating the Efficacy and Safety of Two Doses of the Polyclonal Anti-Tumor Necrosis Factor-α Fragment Antibody AZD9773 in Adult Patients With Severe Sepsis and/or Se...
- A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients Wi...
- Recombinant human activated protein C as a therapy for severe Sepsis: lessons learned?
- Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe Sepsis: the ACCESS randomized trial.
- Drotrecogin alfa (activated) in severe Sepsis - Authors' reply.
- Clinical and Laboratory Diagnosis of Central Nervous System Histoplasmosis.
- Biomarkers: the future.
- At the heart of the matter.
- Sepsis strategies in development.
- Use of corticosteroids in the Sepsis syndrome: what do we know now?
- Tissue factor pathway inhibitor and antithrombin trial results.
- Fever, chills, and chest radiographic infiltrates in a middle-aged woman.
- What's new in antibiotics?
- Antibiotics: what's new?
- Effects of drotrecogin alfa (activated) in human endotoxemia.
- The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe Sepsis (PROWESS): role, methodology, and...
- Systemic host responses in severe Sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated).
- Conflict of interest: authorship issues predominate.
- Sepsis: menu of new approaches replaces one therapy for all.
- Should prophylaxis for Pneumocystis carinii Pneumonia in solid organ transplant recipients ever be discontinued?
- Oseltamivir-resistant 2009-2010 pandemic influenza A (H1N1) in an immunocompromised patient.
- Efficacy and safety of recombinant human activated protein C for severe Sepsis.
- Morphological, molecular, and prognostic aspects of gastric endocrine tumors.
- The tumours of the endocrine pancreas.
- [Patient satisfaction in hemodialysis: a pilot cross-sectional analysis and a review].
- Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative Sepsis caused by Burkholderia pseudomallei.
- Year in review 2008: Critical Care--Sepsis.
- Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe Sepsis.
- Recombinant tissue factor pathway inhibitor in severe community-acquired Pneumonia: a randomized trial.
- Activated protein C for H1N1 influenza? More work to do!
- A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired Pneumonia.
- Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe Sepsis.
- Toll-like receptor-4 antagonist eritoran tetrasodium for severe Sepsis.
Schools
Boston Univ Sch Of Med
Cleve Clin Found
Cleveland Clinic Fdntn
Massachusetts Genl HospHarvard Med Sch
Boston College
Procedures Preformed
- Abscess Incision and Drainage
Conditions Treated
- Cellulitis
- Fever
- Infectious Diseases
- MRSA Infection
- View All
Doctors Specialties
- Infectious Disease Medicine
- Internal Medicine
- Infectious Disease
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
Massachusetts General Hospital -
Cleveland Clinic Foundation -
Boston University School of Medicine
Hospital
-
Scott & White Memorial Hospital -
Beverly Hospital
Drug Facts
| NPI NUMBER | 1811941180 | |
| NPPES Provider LastName | LAROSA | |
| NPPES Provider FirstName | STEVEN | |
| NPPES Provider ZIPCode | 765080001 | |
| NPPES Provider State | TX | |
| Specialty Description | Infectious Disease | |
| Total Claim Count | 121.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1811941180 |
| Last Name Of The Provider | LAROSA |
| First Name Of The Provider | STEVEN |
| View All |
Similar Doctors
|
Dr. Prescott P. Lee, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wei Yang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Irene I. Tsirozidou, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lucas E. Wolf, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thuy Le, MD |
|
|
Dr. Cynthia C. Bjorlie, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alyssa S. Handler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ashish L. Rohira, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hanna Haptu, MD
This Doctor is OpenDoctor Recommended.
|